Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
05/2005
05/26/2005US20050113288 Bonding tissues and cross-linking proteins with naphthalimide compounds
05/26/2005US20050113287 Composition to enhance joint function and repair
05/26/2005US20050113286 Methods for treating congestive heart failure
05/26/2005US20050113284 Drug for regenerating tissue and vessel and method therefor
05/26/2005US20050112748 Low molecular weight gtpase rhot
05/26/2005US20050112745 Transferases
05/26/2005US20050112725 Secreted and transmembrane polypeptides and nucleic acids encoding the same
05/26/2005US20050112714 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins and uses thereof
05/26/2005US20050112713 Methods of using Fab I and compounds modulating Fab I activity
05/26/2005US20050112709 Histone h3methyltransferase polypeptide
05/26/2005US20050112702 Receptor binding assay wherein binding to the CLLD8 protein identifies the compound as being an agonist or antagonist; antiallergens
05/26/2005US20050112692 Screening peptide library; incubation complexing
05/26/2005US20050112681 Isolated human transporter proteins, nucleic acid molecules encoding human, transporter proteins, and uses thereof
05/26/2005US20050112675 Polypeptides gene expressed in fat tissue ; measurement concentration; using antibodies
05/26/2005US20050112669 Glutamate receptor transport protein peptide for use in treatment and prevention of nervous system and cell proliferative disorders
05/26/2005US20050112668 Determination sensitivity for development fat metabolism diosrders by comparison of gene expression levels
05/26/2005US20050112666 Tumor necrosis factor related ligand
05/26/2005US20050112665 Novel VEGF-like factor
05/26/2005US20050112664 Nucleotide sequences coding for the citA gene
05/26/2005US20050112659 Human receptor proteins; related reagents and methods
05/26/2005US20050112642 Fibroblast growth factor receptors and methods for their use
05/26/2005US20050112618 Four helical bundle cytokine family polypeptide for use in treatment, diagnosis and prevention of infection, cardiovascular, metabolic, developmental, skin, bone, inflammatory and autoimmune disorders
05/26/2005US20050112596 APRIL-A novel protein with growth effect
05/26/2005US20050112582 Antibodies for the alpha platelet-derived growth factor receptor
05/26/2005US20050112575 Nucleic acid sequence encoding polypeptides; triggering calcium oscillation in ooctyes ; determination fertility
05/26/2005US20050112574 Isolated nucleic acid; angiogenesis inhibitor
05/26/2005US20050112568 Dgks as modifiers of the p53 pathwha and methods of use
05/26/2005US20050112565 Proteases
05/26/2005US20050112563 Sub-sequences of 2'-deoxy-erythro-pentofuranosyl nucleotides that activate RNase H enzyme; diagnostics; antisense therapeutics
05/26/2005US20050112562 Inhibition of retroviral replication through modulation of the host cell ubiquitylation
05/26/2005US20050112556 Drug screening; endogenous human retrovirus; protein or peptide expressed by said retrovirus
05/26/2005US20050112552 Screening for novel proteins having a functional PDZ domain involves an iterative process by which a peptide recognition unit or PDZ ligand is generated by screening an expression library or a combinatorial peptide library for binders to a known PDZ domain; carbohydrate, oligonucleotide, small drug
05/26/2005US20050112199 Therapeutic regimens for administering drug combinations
05/26/2005US20050112188 Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle
05/26/2005US20050112187 Nucleic acid that expresses a polypeptide such as a cytokine and a phospholipid, both having cytotoxic activity; synergistic combination; side effect reduction
05/26/2005US20050112185 Positively charged lipid and liposome with the lipid
05/26/2005US20050112173 In vivo synthesis of connective tissues
05/26/2005US20050112150 Promoting exfoliation; mixture of polypeptide and protease; skin disorders; antitumor agents
05/26/2005US20050112149 Single-dose taste inhibitor units
05/26/2005US20050112147 Administering a neurotoxin
05/26/2005US20050112146 Administering neurotoxin to infants; cerebral palsy therapy
05/26/2005US20050112134 Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease
05/26/2005US20050112128 Inhibition of protein kinase c-mu (PKD) as a treatment for cardiac hypertrophy and heart failure
05/26/2005US20050112127 Treating with active material having heavy chain variable region of amino acid sequence 7 and light chain variable region of sequence 8; psoriasis, multiple sclerosis, Crohn's disease
05/26/2005US20050112126 Anti-VEGF antibodies
05/26/2005US20050112125 Methods of modulating lipid metabolism and storage
05/26/2005US20050112123 Methods of treating proteinuria
05/26/2005US20050112121 Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
05/26/2005US20050112118 Compositions and methods for treating inflammatory disorders
05/26/2005US20050112117 Molecules and methods for inhibiting shedding of KIM-1
05/26/2005US20050112113 Supplying drugs to len of eye; applyin genergy; breaking bonds in lenses fibers
05/26/2005US20050112107 Prevent adhesion of teeth; using argine, glycine, aspartic acid tripeptides
05/26/2005US20050112103 Genetic engineered vectors encoding human low density lipoproteins ; control sequencing, gene expressionin heptacytes; anticholesterol agents; antilipemic agents
05/26/2005US20050112101 Methods of treating restenosis
05/26/2005US20050112100 Sp1 and Sp3 targeted cancer therapies and therapeutics
05/26/2005US20050112098 Insertion nucleic acid isequences nto cells; retrovirus glycoproteins; respiratory system disorders such as cystic fibrosis
05/26/2005US20050112094 Interferon gamma in the detection and treatment of angiomyolipomas
05/26/2005US20050112093 Combination therapy for HCV infection
05/26/2005US20050112092 Stable, aerosolizable suspensions of proteins in ethanol
05/26/2005US20050112091 Osteoporosis mixture of bone forming agents and nonabsorbent
05/26/2005US20050112090 Enhanced apoptosisinduced by tumor necrosis factor; administering to cell a polypeptide that gene expresses antagonist to tumor necrosis factor; anticancer agents; autoimmune diseases
05/26/2005US20050112087 Pharmaceutical formulations for sustained drug delivery
05/26/2005US20050112079 Administering andothelins, or antagonist thereof, as drug or cosmetics for hair removal or wool harvesting
05/26/2005US20050112063 Methods for inhibiting vascular permeability
05/26/2005US20050112062 Anti-idiotypic vascular endothelial growth factor antibodies and their use as medicaments
05/26/2005US20050112061 Use of a VEGF antagonist in combination with radiation therapy
05/26/2005US20050111299 Device for mixing and/or injecting cements
05/26/2005CA2812856A1 Interleukin-10 antibodies
05/26/2005CA2547474A1 Genes differentially expressed by acutely isolated resident progenitor cells of the human white matter
05/26/2005CA2546077A1 Vaccine and method for treatment of neurodegenerative diseases
05/26/2005CA2545841A1 Use of lipopeptides for activating t lymphocytes through the skin
05/26/2005CA2545733A1 Methods for monitoring il-18
05/26/2005CA2545718A1 Methods of using gelsolin to treat or prevent bacterial sepsis
05/26/2005CA2545709A1 Methods and compositions for the treatment of b cell lymphomas and other cancers
05/26/2005CA2545458A1 Dry recombinant human alpha 1-antitrypsin formulation
05/26/2005CA2545325A1 Compositions for reducing bacterial carriage and cns invasion and methods of using same
05/26/2005CA2545255A1 Interleukin-10 antibodies
05/26/2005CA2545194A1 Pharmaceutical compositions including low dosages of desmopressin
05/26/2005CA2545152A1 Compositions and methods of treating neurological diseases
05/26/2005CA2545062A1 Selective inhibitors of nuclear factor-kb activation and uses thereof
05/26/2005CA2544820A1 Bacterial expression of protease inhibitors and variants thereof
05/26/2005CA2544816A1 Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
05/26/2005CA2544603A1 Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
05/26/2005CA2544591A1 Methods of using and compositions comprising a jnk inhibitor for the treatment and management of asbestos-related diseases and disorders
05/26/2005CA2544589A1 Methods of using and compositions comprising pde4 modulators for the treatment and management of asbestos-related diseases and disorders
05/26/2005CA2544506A1 Use of strain of lactobacillus and byproducts thereof for inhibiting formation of blood vessels
05/26/2005CA2544421A1 Combination of a farnesyl transferase inhibitor with an antihormonal agent for the treatment of breast cancer
05/26/2005CA2544308A1 Cytokine antagonist molecules
05/26/2005CA2544239A1 Methods for the production of apolipoproteins in transgenic plants
05/26/2005CA2543811A1 Compositions and methods for diagnosing and treating mental disorders
05/26/2005CA2543806A1 Combined cosmetic or therapeutic preparation
05/26/2005CA2541944A1 Microparticles comprising somatostatin analogues
05/26/2005CA2536168A1 Intravascular devices and fibrosis-inducing agents
05/26/2005CA2536041A1 Medical implants and fibrosis-inducing agents
05/26/2005CA2527904A1 Lactoferrin as an adjuvant in cancer vaccines
05/25/2005EP1533619A2 Specific markers for metabolic syndrome
05/25/2005EP1533617A1 Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
05/25/2005EP1533374A1 Novel peptides having camp producing activity
05/25/2005EP1533372A1 Human phospholipase C-Alpha and DNA sequence encoding the same
05/25/2005EP1533318A1 Prodrugs of thrombin inhibitors
1 ... 1438 1439 1440 1441 1442 1443 1444 1445 1446 1447 1448 1449 1450 1451 1452 1453 1454 1455 1456 1457 1458 ... 3163